The Indian Journal of Chest Diseases and Allied Sciences

Register      Login

VOLUME 64 , ISSUE 3 ( July-September, 2022 ) > List of Articles

Original Article

Sputum Inflammatory Cells and their Impact on Asthma Control in Adults: A Prospective Study

Anil Kumar Jain, Prabhpreet Sethi, Bharat Janpathi, Shalini Mullick

Keywords : Asthma, Eosinophilic, Mixed granulocytes, Noneosinophilic, Phenotypes, Paucigraulocytes

Citation Information : Jain AK, Sethi P, Janpathi B, Mullick S. Sputum Inflammatory Cells and their Impact on Asthma Control in Adults: A Prospective Study. Indian J Chest Dis Allied Sci 2022; 64 (3):192-195.

DOI: 10.5005/jp-journals-11007-0052

License: CC BY-NC 4.0

Published Online: 08-12-2022

Copyright Statement:  Copyright © 2022; The Author(s).


Background: Asthma is broadly categorized as eosinophilic or noneosinophilic. Noneosinophilic asthma (NEA) can be paucigranulocytic asthma (PGA), mixed granulocytic asthma (MGA), or neutrophilic asthma (NeuA). A relationship between the cytological type of inflammation and response to treatment with inhaled corticosteroids (ICS) in asthma has been of great interest. The objective of the current study was to predict the control of asthma according to sputum inflammatory cells. Materials and methods: A total of 58 patients were evaluated. Sputum was induced and sent for cytological examination. Patients were prescribed controller and reliever medications as per the GINA guidelines. Accordingly, subjects were divided into eosinophilic, neutrophilic, mixed granulocytic, and paucigranulocytic asthma. The response to treatment was classified as poorly controlled based on ACT score. Results: Out of 58 patients, eosinophilic asthma (EA) was 24% and noneosinophilic 76% (NeuA 17%, MGA 23%, and PGA 36%). After treatment, 14 (24.13%) patients were found poorly controlled. Poor control was in 5.17% among EA and 18.97% in NEA phenotypes. Poor control was significantly higher in females, NeuA, and MGA. Peripheral eosinophilia affects control of asthma adversely. Conclusion: Pretreatment sputum analysis can predict the asthma control and steroid responsiveness. Mixed granulocytic asthma and NeuA are difficult to control, and PGA is the best responder.

  1. Grootendorst DC, Sont JK, Willems LN, et al. Comparison of inflammatory cell counts in asthma: Induced sputum vs bronchoalveolar lavage and bronchial biopsies Clin Exp Allergy 1997;27(7):769–779. PMID: 9249269.
  2. Arron JR, Choy DF, Scheerens H, et al. Noninvasive biomarkers that predict treatment benefit from biologic therapies in asthma. Ann Am Thorac Soc 2013;10:S206–S213. DOI: 10.1513/AnnalsATS.201303-047AW.
  3. Thomson NC. Novel approaches to the management of noneosinophilic asthma. Ther Adv Respir Dis 2016;10(3):211–234. DOI: 10.1177/1753465816632638.
  4. Moore WC, Hastie AT, Li X, et al. Sputum neutrophil counts are associated with more severe asthma phenotypes using cluster analysis. J Allergy Clin Immunol 2014;133(6):1557–1563.e5. DOI: 10.1016/j.jaci.2013.10.011.
  5. Kamath AV, Pavord ID, Ruparelia PR, et al. Is the neutrophil the key effector cell in severe asthma? Thorax 2005;60(7):529–530. DOI: 10.1136/thx.2005.043182.
  6. Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 2014;371(13):1189–1197. DOI: 10.1056/NEJMoa1403291.
  7. Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014;371(13):1198–1207. DOI: 10.1056/NEJMoa1403290.
  8. Westerhof GA, Korevaar DA, Amelink M, et al. Biomarkers to identify sputum eosinophilia in different adult asthma phenotypes. Eur Respir J 2015;46(3):688–696. DOI: 10.1183/09031936.00012415.
  9. Ntontsi P, Loukides S, Bakakos P, et al. Clinical, functional and inflammatory characteristics in patients with paucigranulocytic stable asthma: Comparison with different sputum phenotypes. Allergy 2017;72(11):1761–1767. DOI: 10.1111/all.13184.
  10. Hastie AT, Moore WC, Meyers DA, et al. Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes. J Allergy Clin Immunol 2010;125(5):1028–1036.e13. DOI: 10.1016/j.jaci.2010.02.008.
  11. Bousquet J, Barnes N, Gibbs M, et al. Asthma control using fluticasone propionate/salmeterol in Asian and non-Asian populations: A post hoc analysis of the GOAL study. BMC Pulm Med 2017;17(1):75. DOI: 10.1186/s12890-017-0410-x.
  12. Rogala B, Majak P, Gluck J, et al. Asthma control in adult patients treated with a combination of inhaled corticosteroids and long-acting β2-agonists: A prospective observational study. Pol Arch Intern Med 2017;127(2):100–106. DOI: 10.20452/pamw.3899.
  13. Douwes J, Gibson P, Pekkanen J, et al. Non-eosinophilic asthma: Importance and possible mechanisms. Thorax 2002;57(7):643–648. DOI: 10.1136/thorax.57.7.643.
  14. Brown HM. Treatment of chronic asthma with prednisolone; significance of eosinophils in the sputum. Lancet 1958;2(7059):1245–1247. DOI: 10.1016/s0140-6736(58)91385-0.
  15. Pavord ID, Brightling CE, Woltmann G, et al. Non-eosinophilic corticosteroid unresponsive asthma. Lancet 1999;353(9171):2213–2214. DOI: 10.1016/S0140-6736(99)01813-9.
  16. Wenzel SE, Schwartz LB, Langmack EL, et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999;160(3):1001–1008. DOI: 10.1164/ajrccm.160.3.9812110.
  17. McGrath KW, Icitovic N, Boushey HA, et al. A large subgroup of mild-to-moderate asthma is persistently noneosinophilic. Am J Respir Crit Care Med 2012;185(6):612–619. DOI: 10.1164/rccm.201109-1640OC.
  18. Jatakanon A, Kharitonov S, Lim S, et al. Effect of differing doses of inhaled budesonide on markers of airway inflammation in patients with mild asthma. Thorax 1999;54(2):108–114. DOI: 10.1136/thx.54.2.108.
  19. Demarche S, Schleich F, Henket M, et al. Detailed analysis of sputum and systemic inflammation in asthma phenotypes: Are paucigranulocytic asthmatics really non-inflammatory? BMC Pulm Med 2016; 16:46. DOI: 10.1186/s12890-016-0208-2.
  20. Berry M, Morgan A, Shaw DE, et al. Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma. Thorax 2007;62(12):1043–1049. DOI: 10.1136/thx.2006.073429.
  21. Godon P, Boulet L-P, Malo J-L, et al. Assessment and evaluation of symptomatic steroid-naive asthmatics without sputum eosinophilia and their response to inhaled corticosteroids. Eur Respir J 2002;20:1364–1369. DOI: 10.1183/09031936.02.00017502.
  22. Hastie AT, Moore WC, Li H, et al. Biomarker surrogates do not accurately predict sputum eosinophil and neutrophil percentages in asthmatic subjects. J Allergy Clin Immunol 2013;132(1):72–80. DOI: 10.1016/j.jaci.2013.03.044.
  23. Casciano J, Krishnan JA, Small MB, et al. Value of peripheral blood eosinophil markers to predict severity of asthma. BMC Pulm Med 2016;16(1):109. DOI: 10.1186/s12890-016-0271-8.
  24. Mukherjee M, Nair P. Blood or sputum eosinophils to guide asthma therapy? Lancet Respir Med 2015;3(11):824–825. DOI: 10.1016/S2213-2600(15)00419-1.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.